X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs SUN PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB SUN PHARMA DR. REDDYS LAB/
SUN PHARMA
 
P/E (TTM) x 27.2 15.3 177.2% View Chart
P/BV x 2.8 3.6 77.7% View Chart
Dividend Yield % 1.0 0.2 475.9%  

Financials

 DR. REDDYS LAB   SUN PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
SUN PHARMA
Mar-16
DR. REDDYS LAB/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs4,3831,201 365.0%   
Low Rs2,750706 389.3%   
Sales per share (Unadj.) Rs920.1117.5 783.3%  
Earnings per share (Unadj.) Rs126.119.6 643.5%  
Cash flow per share (Unadj.) Rs183.023.8 768.6%  
Dividends per share (Unadj.) Rs20.001.00 2,000.0%  
Dividend yield (eoy) %0.60.1 534.7%  
Book value per share (Unadj.) Rs685.8130.5 525.6%  
Shares outstanding (eoy) m170.612,406.60 7.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.98.1 47.8%   
Avg P/E ratio x28.348.7 58.1%  
P/CF ratio (eoy) x19.540.1 48.7%  
Price / Book Value ratio x5.27.3 71.2%  
Dividend payout %15.95.1 310.8%   
Avg Mkt Cap Rs m608,4812,294,813 26.5%   
No. of employees `00021.714.7 146.9%   
Total wages/salary Rs m31,87447,971 66.4%   
Avg. sales/employee Rs Th7,244.419,169.8 37.8%   
Avg. wages/employee Rs Th1,470.93,253.0 45.2%   
Avg. net profit/employee Rs Th992.83,197.9 31.0%   
INCOME DATA
Net Sales Rs m156,978282,697 55.5%  
Other income Rs m2,6936,170 43.6%   
Total revenues Rs m159,671288,867 55.3%   
Gross profit Rs m34,58783,239 41.6%  
Depreciation Rs m9,70510,135 95.8%   
Interest Rs m8244,769 17.3%   
Profit before tax Rs m26,75174,505 35.9%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m0-6,852 0.0%   
Tax Rs m5,2379,349 56.0%   
Profit after tax Rs m21,51447,159 45.6%  
Gross profit margin %22.029.4 74.8%  
Effective tax rate %19.612.5 156.0%   
Net profit margin %13.716.7 82.2%  
BALANCE SHEET DATA
Current assets Rs m118,201308,646 38.3%   
Current liabilities Rs m68,368132,477 51.6%   
Net working cap to sales %31.762.3 50.9%  
Current ratio x1.72.3 74.2%  
Inventory Days Days6083 72.3%  
Debtors Days Days9788 110.4%  
Net fixed assets Rs m72,265133,606 54.1%   
Share capital Rs m8532,407 35.4%   
"Free" reserves Rs m111,548266,909 41.8%   
Net worth Rs m117,009314,042 37.3%   
Long term debt Rs m10,69031,167 34.3%   
Total assets Rs m200,104542,196 36.9%  
Interest coverage x33.516.6 201.3%   
Debt to equity ratio x0.10.1 92.1%  
Sales to assets ratio x0.80.5 150.5%   
Return on assets %11.29.6 116.6%  
Return on equity %18.415.0 122.4%  
Return on capital %21.617.8 121.7%  
Exports to sales %46.314.0 330.5%   
Imports to sales %9.03.1 284.9%   
Exports (fob) Rs m72,61839,572 183.5%   
Imports (cif) Rs m14,0508,882 158.2%   
Fx inflow Rs m75,40542,171 178.8%   
Fx outflow Rs m27,11521,583 125.6%   
Net fx Rs m48,29020,588 234.5%   
CASH FLOW
From Operations Rs m40,47667,694 59.8%  
From Investments Rs m-19,421-44,549 43.6%  
From Financial Activity Rs m-17,009-19,243 88.4%  
Net Cashflow Rs m4,0463,902 103.7%  

Share Holding

Indian Promoters % 25.5 63.7 40.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 5.1 105.3%  
FIIs % 35.3 23.0 153.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 8.3 184.3%  
Shareholders   75,885 133,026 57.0%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 18, 2017 03:37 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS